Skyrizi continues to outperform as AbbVie looks to fill Humira gap

Despite the effects of the COVID-19 outbreak, AbbVie now expects 2020 sales of psoriasis drug Skyrizi to reach about $1.4 billion as the therapy again exceeded expectations in the year’s first quarter, suggesting the company will likely have a

Read the full 399 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE